Kooman & Associates’s GSK GSK Stock Holding History

Kooman & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$277K	Buy	5,741 +49	+0.9%	+$2.5K	0.07%	49
2026 Q2	$298K	Hold	5,692	–	–	0.08%	46
2026 Q1	$314K	Sell	5,692 -1,562	-22%	-$84.6K	0.09%	40
2025 Q4	$356K	Sell	7,254 -561	-7%	-$26.2K	0.11%	38
2025 Q3	$337K	Sell	7,815 -19	-0.2%	-$742	0.1%	40
2025 Q2	$301K	Buy	7,834 +2,142	+38%	+$81.8K	0.1%	41
2025 Q1	$221K	Buy	+5,692	New	+$208K	0.08%	45
2024 Q4	–	Sell	-6,229	Closed	-$255K	–	49
2024 Q3	$255K	Hold	6,229	–	–	0.09%	40
2024 Q2	$240K	Hold	6,229	–	–	0.1%	37
2024 Q1	$267K	Sell	6,229 -40	-0.6%	-$1.65K	0.11%	33
2023 Q4	$232K	Buy	6,269 +40	+0.6%	+$1.44K	0.1%	36
2023 Q3	$226K	Hold	6,229	–	–	0.11%	35
2023 Q2	$222K	Sell	6,229 -47	-0.7%	-$1.69K	0.11%	37
2023 Q1	$223K	Buy	6,276 +582	+10%	+$20.4K	0.12%	36
2022 Q4	$200K	Buy	+5,694	New	+$190K	0.2%	39

Other funds holding GSK

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

Bell Bank Fargo, North Dakota $2.66B AUM 18.07% 1-Year Est. Return

Keating Investment Counselors Delray Beach, Florida $382M AUM 16.71% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

Kooman & Associates's GSK Position: Q3 2026 in Review

Kooman & Associates increased its GSK (GSK) stake by 0.86% in Q3 2026, buying an estimated $2.5K and bringing the position to 5,741 shares worth $277K. The position accounts for 0.07% of the portfolio, ranked #49.

Kooman & Associates first reported a position in GSK in Q4 2022 and has held it in 15 quarters since. The position peaked at $356K in Q4 2025. 233 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Kooman & Associates held 5,741 shares of GSK worth $277K as of Q3 2026.
Kooman & Associates bought 49 GSK shares in Q3 2026, an estimated $2.5K.
GSK made up 0.07% of Kooman & Associates's portfolio in Q3 2026, its #49 holding.
Kooman & Associates first reported a position in GSK in Q4 2022 and has held it in 15 quarters since.
Kooman & Associates's GSK position peaked at $356K in Q4 2025.
233 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Kooman & Associates's 13F filing for Q3 2026, filed 21 Oct 2026.